Eli Lilly became the first pharmaceutical company valued over $1 trillion, driven by strong revenue growth and promising drugs like retatrutide and orforglipron. The company reported a 47.67% revenue increase in Q2 and raised its 2026 revenue guidance. Analysts see potential for nearly 20% stock price upside over the next year, with a bull case target above $1,600 if new obesity treatments succeed. Risks include pricing pressure and competition from Novo Nordisk. Overall, Eli Lilly's growth outlook remains strong compared to peers like Novo Nordisk and Merck.
Aktis Oncology, a clinical-stage radiopharmaceutical company, closed at $25.00 on August 18, 2026, with a market cap of $1.4 billion and $517.3 million in cash, supporting operations into 2029. Its lead candidate targets Nectin-4 with trial data expe...
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
J.P. Morgan Life Sciences Private Capital has named Bruce N. Rogers, Ph.D., as a Venture Partner. Dr. Rogers brings extensive experience in drug discovery and development, having led significant roles at Morphic Therapeutic and Pfizer. His expertise ...
Packaged food stocks have significantly underperformed pharmaceutical stocks over the past year, driven largely by concerns over GLP-1 weight-loss drugs impacting food demand. While Eli Lilly's stock soared 74%, many food companies like Campbell's an...
Three major large-cap growth ETFs—Schwab SCHG, Vanguard VUG, and Invesco QQQ—offer different approaches to capturing growth, especially in AI and tech sectors. QQQ, tracking the Nasdaq-100, outperformed with a 10-year return of about 513%, benefiting...
